Compounds in Clinical Phase III and Beyond
作者： Torsten Kessler , Michael Bayer , Christian Schwöppe , Rüdiger Liersch , Rolf M. Mesters
DOI: 10.1007/978-3-540-78281-0_9
关键词:
摘要: Targeted therapies against cancer have become more and important. In particular, the inhibition of tumor angiogenesis vascular targeting been focus new treatment strategies. Numerous substances were developed as inhibitors evaluated in clinical trials for safety, tolerance, efficacy. With positive study results, some these molecules already approved use. For example, this is true endothelial growth factor neutralizing antibody bevacizumab (BEV) metastatic colorectal cancer, nonsmall cell lung renal breast cancer. The tyrosine kinase (TK) sorafenib sunitinib well hepatocellular carcinoma, has also gastrointestinal stroma tumors. chapter we try to give an overview currently investigated Phase III studies beyond with regard antiangiogenesis therapy.
springer.com
sci-hub.st 参考文章(130)
Ronald Bukowski, David Cella, Kathleen Gondek, William P Bro, Katie Langefeld, Jacquelyn George, Rahul Dhanda, Susan Yount, Celeste Kelly, Hongyan Du, Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). The journal of supportive oncology. ,vol. 4, pp. 191- 199 ,(2006)
M. M. Cooney, P. Savvides, S. Agarwala, D. Wang, S. Flick, S. Bergant, S. Bhakta, P. Lavertu, J. Ortiz, S. Remick, Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC) Journal of Clinical Oncology. ,vol. 24, pp. 5580- 5580 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.5580
Xiping Li, Eddie Reed, Yi Zhang, Jie Wang, Yuanlin Liu, Wei Jiang, Zengli Wang, Q Quentin Li, Xuyi Liu, Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells Anticancer Research. ,vol. 23, pp. 2481- 2487 ,(2003)
David J. Chaplin, Michael R. L. Stratford, Borivoj Vojnovic, Rosalind J. Locke, Gillian M. Tozer, Francesca Lee, Susan M. Galbraith, Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Research. ,vol. 21, pp. 93- 102 ,(2001)
Eu-Yul Choi, Seung-Taek Lee, Jungheum Yeon, Young-Guen Kwon, Kyu-Won Kim, Young-Mi Kim, Jin-Wook Jang, Ok-Hee Lee, Endostatin Inhibits Endothelial and Tumor Cellular Invasion by Blocking the Activation and Catalytic Activity of Matrix Metalloproteinase 2 Cancer Research. ,vol. 60, pp. 5410- 5413 ,(2000)
Lila Adnane, Pamela A. Trail, Ian Taylor, Scott M. Wilhelm, Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature Methods in Enzymology. ,vol. 407, pp. 597- 612 ,(2006) , 10.1016/S0076-6879(05)07047-3
Napoleone Ferrara, Kenneth J Hillan, Hans-Peter Gerber, William Novotny, None, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature Reviews Drug Discovery. ,vol. 3, pp. 391- 400 ,(2004) , 10.1038/NRD1381
Dieter Marmé, Joachim Drevs, Harald Hugenschmidt, Clemens Unger, Jeanette Wood, Georg Martiny-Baron, Helmut Madjar, Christine Wittig, Marianne Müller, Inga Hofmann, Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model Cancer Research. ,vol. 60, pp. 4819- 4824 ,(2000)
Vivien E. Prise, George R. Pettit, Graham G. Dark, Sally A. Hill, Dai J. Chaplin, Gillian M. Tozer, Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Research. ,vol. 57, pp. 1829- 1834 ,(1997)
Jeanette M Wood, G Bold, Elizabeth Buchdunger, R Cozens, Stefano Ferrari, Jörg Frei, F Hofmann, Jürgen Mestan, H Mett, Terence O’Reilly, Elke Persohn, Johannes Rösel, Christian Schnell, David Stover, A Theuer, Harry Towbin, Fritz Wenger, K Woods-Cook, A Menrad, Gerhard Siemeister, M Schirner, Karl-Heinz Thierauch, Martin R Schneider, J Drevs, G Martiny-Baron, F Totzke, Dieter Marmé, PTK787/ZK 222584, a Novel and Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Impairs Vascular Endothelial Growth Factor-induced Responses and Tumor Growth after Oral Administration Cancer Research. ,vol. 60, pp. 2178- 2189 ,(2000)